Anti-retroviral Drugs Market by Drugs Classes (Integrase Inhibitor, Protease Inhibitor, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-nucleoside Reverse Transcriptase Inhibitors, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

Anti Retroviral Drugs Market Outlook 2031

The Anti-retroviral Drugs Market was USD 32.49 Billion in 2022 and is likely to reach USD 58.24 Billion, expanding at  CAGR of 6.7% during 2023 – 2031. The growth of the market is attributed to the rising burden of HIV, increasing investment in research and development and growing demand for of new and efficient drugs.

Antiretroviral drugs (ARV) are used to treat HIV. Approximately 37.9 million people worldwide are infected with HIV/AIDS. In 2018, an estimated 1.7 million people worldwide were infected with HIV. For unstable HIV strains, antiretroviral therapy can inhibit about 80% of HIV replication.

Anti Retroviral Drugs Market Trends, Drivers, Restraints, and Opportunities

• Increasing incidence of HIV is expected to boost the market growth during the forecast period.
• Rapid growth of the healthcare industry is one of the major factors boosting the market growth in the coming years.
• Increasing geriatric population and availability of products being developed for the treatment of HIV are anticipated to drive the market growth during forecast period.
• High price of anti-retroviral drugs and presence of generic drugs are expected to hamper the market growth.
• Rising awareness about drugs treatment and initiatives taken by government and other non-profit organizations by launching educational programs can proliferate the growth of the market.
• Rising R&D investment and ongoing development of new efficient drugs to reduce the therapy cost are expected to create immense opportunities for the market players in the projected timeline.

Scope of Anti Retroviral Drugs Market Report

The report on the global Anti-retroviral Drugs Market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Anti-Retroviral drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Drugs Classes (Integrase Inhibitor, Protease Inhibitor, Multi-Class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, and Others)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	ViiV Healthcare, Merck & Co Inc., Gilead Sciences Inc., Bristol-Myers Squibb Company, and Boehringer Ingelheim International GmbH

Anti-retroviral Drugs Market Segment Insights

Multi-class combination products segment is projected to represent a major market share

Based on drug classes, the market is segmented into integrase inhibitor, protease inhibitor, multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and others. The multi-class combination products segment is expected to represent a key market share during the forecast period owing to the rising number of multi-type combination products due to the increasing burden of HIV and the approval of new drugs.

According to the World Health Organization, about 770,000 people died of HIV in 2018. Many companies are focusing on development of innovative ARV therapy products to maintain competitive advantage and expand into new regional markets. Additionally, increasing funding for ARV drug development is expected to drive the growth of the market segment.

The nucleoside reverse transcriptase inhibitors segment and non-nucleoside reverse transcriptase inhibitors segment are anticipated to expand at a rapid pace during the forecast period. Some of the most widely used drugs in resource-limited areas use reverse transcriptase inhibitors due to the low genetic barriers. Moreover, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors are used to combat HIV and hepatitis infections through highly effective ARV therapy.

Integrase inhibitors, also known as integrase nuclear strand transfer inhibitors or INSTI, block the viral enzyme integrase, which is responsible for integrating viral DNA into the DNA of infected cells. Several integrase inhibitors are undergoing clinical trials. Raltegravir was the first drug approved by the FDA in October 2007. Raltegravir has two metal binding groups that compete with two Mg²⁺ ions for the substrate at the metal binding site of integrase. In early 2014, elvitegravir and dolutegravir were two other clinically approved integrase inhibitors.

Protease inhibitors block viral proteases, which are necessary for the formation of mature virus particles after budding from the host membrane. In particular, these drugs prevent the cleavage of gag and gag/pol precursor proteins. Viral particles produced in the presence of protease inhibitors are defective and in most cases are not infectious.

Some of the examples of HIV protease inhibitors are lopinavir, indinavir, nelfinavir, amprenavir and ritonavir. Darunavir and atazanavir are recommended as first-line treatments. Sensing inhibitors have similar effects by combining with glycosaminoglycans (GAGs), but the development of two experimental drugs in this category, Bevirimat and Vivecone, stopped in 2010. High resistance to certain protease inhibitors, second-generation drugs have been developed that can effectively combat other drug-resistant variants of HIV.

North America is expected to dominate the market

On the basis of regions, the anti-retroviral drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth is attributed to presence of market players, availability of healthcare infrastructure, rising awareness among citizens, and initiatives taken by the US government.

More than 56,000 new cases of HIV infection are found in the US each year, and about 20 out of every 100 infected people does not know that they are infected with the virus. The high coverage of ART and increasing attention to branded prescription drugs are expected to drive market growth in the region.

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-retroviral Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Anti-retroviral Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Anti-retroviral Drugs Market - Supply Chain
  4.5. Global Anti-retroviral Drugs Market Forecast
     4.5.1. Anti-retroviral Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Anti-retroviral Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Anti-retroviral Drugs Market Absolute $ Opportunity
5. Global Anti-retroviral Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Anti-retroviral Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Anti-retroviral Drugs Demand Share Forecast, 2019-2026
6. North America Anti-retroviral Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Anti-retroviral Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Anti-retroviral Drugs Demand Share Forecast, 2019-2026
7. Latin America Anti-retroviral Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Anti-retroviral Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Anti-retroviral Drugs Demand Share Forecast, 2019-2026
8. Europe Anti-retroviral Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Anti-retroviral Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Anti-retroviral Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Anti-retroviral Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Anti-retroviral Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Anti-retroviral Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Anti-retroviral Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Anti-retroviral Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Anti-retroviral Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Anti-retroviral Drugs Market: Market Share Analysis
  11.2. Anti-retroviral Drugs Distributors and Customers
  11.3. Anti-retroviral Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. ViiV Healthcare
     11.4.2. Merck & Co Inc.
     11.4.3. Gilead Sciences Inc.
     11.4.4. Bristol-Myers Squibb Company
     11.4.5. Boehringer Ingelheim International GmbH